Zevra Therapeutics, Inc. (ZVRA)
12.30
+0.24
(+1.99%)
USD |
NASDAQ |
Sep 02, 16:00
12.30
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Research and Development Expense (Annual) : 12.55M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 12.55M |
| December 31, 2024 | 35.71M |
| December 31, 2023 | 38.80M |
| December 31, 2022 | 18.86M |
| December 31, 2021 | 9.904M |
| December 31, 2020 | 8.57M |
| December 31, 2019 | 19.11M |
| Date | Value |
|---|---|
| December 31, 2018 | 41.76M |
| December 31, 2017 | 20.59M |
| December 31, 2016 | 20.47M |
| December 31, 2015 | 13.93M |
| December 31, 2014 | 11.92M |
| December 31, 2013 | 3.367M |
| December 31, 2012 | 2.995M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Innoviva, Inc. | 30.60M |
| Collegium Pharmaceutical, Inc. | 0.00 |
| Johnson & Johnson | 14.83B |
| Ligand Pharmaceuticals, Inc. | 81.18M |
| Harrow, Inc. | 12.85M |